Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models
HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian and breast cancer.
Alvotech to acquire Baliopharm
Acquisition provides Alvotech with complimentary capabilities in biosimilar development.
Catalent introduces Peel-ID safe storage label to improve storage and retrieval of patient kits
Peel-ID greatly reduces the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers.
Aptar Pharma provides unit-dose nasal spray technology for the treatment of opioid overdose
The delivery system is for Adept Pharma's Narcan - the first FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.
Martindale Pharma expands European commercial activities to include France
Launch of early access programme for Noyada, first novel oral liquid formulation of Captopril targeting paediatric cardiovascular conditions and type 1 diabetic nephropathy.
Catalyst Pharmaceuticals to reduce workforce as part of operating expense management plan
Reduction is part of the company's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome and congenital myasthenic sy...
ProBioGen to license GlymaxX to Thermo Fisher Scientific for use in developing allergy diagnostics
Afucosylation can enable more precise assessment of allergic sensitization.
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped early
Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-planned interim analysis.
FDA grants Genentech’s cancer immunotherapy Tecentriq Accelerated Approval for people with a specific type of advanced bladder cancer
First and only anti-PDL1 cancer immunotherapy approved by the FDA.